Beijing Konruns Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceuticals in China and internationally. The company offers agkistrodon halys hemocoagulase under Suling trade name. It is also involved in the development of drug candidates, including ZY5301 that is in phase 3 clinical trials for the treatment of chronic pelvic pain in sequelae of pelvic inflammatory disease; and KC1036, which is in phase 2 clinical trial for the treatment of solid tumors. The company was founded in 2003 and is headquartered in Beijing, China.
Frequently asked questions
What sector does Beijing Konruns Pharmaceutical Co Ltd (603590) operate in?
Beijing Konruns Pharmaceutical Co Ltd belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Beijing Konruns Pharmaceutical Co Ltd (603590) current stock price?
As of the latest data, Beijing Konruns Pharmaceutical Co Ltd stock price is CN¥29.38, with a previous close of CN¥29.92. Beijing Konruns Pharmaceutical Co Ltd lost -CN¥0.54 in the last trading session, representing a -1.8% loss.
What is Beijing Konruns Pharmaceutical Co Ltd (603590) current market capitalization?
Beijing Konruns Pharmaceutical Co Ltd market cap is approximately 4.67 billion.
What is Beijing Konruns Pharmaceutical Co Ltd (603590) Earnings Per Share (EPS)?
The trailing EPS is CN¥1.07.
What is Beijing Konruns Pharmaceutical Co Ltd (603590) Price-to-Earnings (P/E) ratio?
Beijing Konruns Pharmaceutical Co Ltd current P/E ratio is 27.46.
Does Beijing Konruns Pharmaceutical Co Ltd (603590) pay dividends?
No. Beijing Konruns Pharmaceutical Co Ltd does not pay a dividend.
What is Beijing Konruns Pharmaceutical Co Ltd (603590) beta (volatility) score?
Beijing Konruns Pharmaceutical Co Ltd has a beta of 0.395, indicating lower volatility than the overall market.
